Scientists test Two-Pronged attack on tough blood cancer
NCT ID NCT05016947
Summary
This study is testing the safety and effectiveness of combining two drugs, venetoclax and inotuzumab ozogamicin, for adults with B-cell acute lymphoblastic leukemia (B-ALL) that has come back or hasn't responded to previous chemotherapy. The main goal is to find the highest safe dose of the combination. Participants will receive treatment for about 6 to 9 months and be followed for two years.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02115, United States
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02115, United States
Conditions
Explore the condition pages connected to this study.